Eight years have passed since the 2018 Lancet Series on preconception health landed with enough weight to shift conversations in reproductive medicine. The question now isn’t whether it mattered. It’s whether the field actually moved.

The Series, led by Judith Stephenson, didn’t emerge from nowhere. It crystallized an argument that had been accumulating across decades of reproductive research: that what happens to both men and women before conception shapes not just pregnancy outcomes, but children’s health across their entire lives. Stephenson’s team gave that argument a scaffold. Three prongs, one framework, addressing the biological, individual, and public health dimensions of preconception care. Not a narrow focus on women approaching pregnancy. A population-wide rethinking of who preconception health belongs to.

That’s a meaningful distinction, and it’s worth sitting with before we tally what came next.

---

What the Series got right, it got substantially right. Preconception health as a concept had long been tethered, in clinical practice, almost exclusively to women preparing for pregnancy. Stephenson’s 2018 Series disrupted that framing by centering both partners. Paternal contributions, including sperm DNA integrity, body weight, alcohol use, and occupational chemical exposures, were positioned not as footnotes but as genuine contributors to conception success and the downstream health of offspring. That conceptual shift has taken hold in the research literature, at least partially.

The biological case deserves careful review because it’s the foundation everything else rests on. Decades of study have established that maternal nutritional status, particularly folate, iodine, and iron, affects embryogenesis at developmental windows that open before most women know a pregnancy exists. The Series extended the biological frame to include paternal factors in ways the clinical community hadn’t systematically engaged with before.

Epigenetic mechanisms sit at the center of this. Evidence drawn from animal models and human observational studies indicates that a father’s diet and metabolic condition can influence gene expression in offspring via sperm epigenomes, operating independently of the DNA sequence itself. That’s not a small claim. It’s also not yet a clean one. Confounding remains a serious problem in the human observational literature; most studies can’t disentangle paternal epigenetic effects from shared household environments, genetic predispositions, or socioeconomic variables that affect both parents simultaneously.

Still, the signal is persistent enough that dismissing it would be premature.

---

The gap between biological plausibility and clinical implementation is where the 2018 framework has struggled most visibly. Stephenson’s three-pronged architecture proposed changes at the biological, individual, and public health priority levels simultaneously. Eight years on, progress across those three domains has been deeply uneven.

At the biological level, research output has increased. That’s real. Journals have published substantially more on paternal preconception factors since 2018, and funding bodies in several countries have recognized preconception health as a research category worth investing in. But volume of publication isn’t clinical implementation, and the translation gap here is wide.

At the individual level, preconception counseling for people with chronic conditions, one of the Series’ clearest recommendations, remains inconsistently delivered in most health systems. Primary care providers often don’t initiate preconception conversations outside of explicitly reproductive consultations. Men are rarely included. The infrastructure to support routine, population-level preconception assessment simply doesn’t exist in most settings, including many high-income countries that have the resources to build it.

At the public health level, the shortfall is starker. Stephenson’s framework called for clinical and public health infrastructure capable of reaching people across the reproductive lifespan, not just those actively trying to conceive. That vision has not materialized in any systematic way. What exists tends to be fragmented, under-resourced, and concentrated in antenatal rather than preconception settings.

---

The 2018 Series was published in The Lancet, carrying identifiers that placed it squarely in the high-visibility literature. Article identifiers from that publication, including reference codes 00707 and 6736, appear in the citation trail across the subsequent preconception literature. Whether citation volume translates to changed behavior at the clinical encounter level is a different, and harder, empirical question.

It doesn’t, not reliably. The history of medicine is not short on influential frameworks that generated substantial citation counts without producing proportional changes in practice. The 2018 Series isn’t unique in facing that gap. But the gap is real, and pretending otherwise wouldn’t serve the field.

---

What does the evidence actually support, eight years out? Several things, stated carefully.

The biological case for preconception health affecting offspring outcomes is stronger now than it was in 2018. That case still carries important methodological caveats, particularly around confounding in observational designs, but the convergence of animal model data with human epidemiological patterns is notable. Dismissing the biological plausibility of paternal epigenetic contributions to offspring health would require ignoring a growing and reasonably consistent body of evidence.

The individual-level interventions proposed by Stephenson’s team have the clearest evidence base when they’re actually delivered. Preconception folic acid supplementation, optimization of chronic disease management before conception, and reduction of teratogenic medication exposure are each supported by evidence that didn’t emerge from the 2018 Series but was synthesized and amplified by it. The problem isn’t the evidence. It’s the delivery infrastructure.

The public health framing, the most ambitious of the three prongs, remains the most aspirational. We’re not close to population-level preconception health systems in most countries. That’s a funding problem, a political priority problem, and a health system design problem simultaneously.

---

Judith Stephenson addressed the gap directly in commentary following the Series’ publication. “The evidence is there,” she said. “What we lack is the system to act on it consistently.”

That observation has aged well. The Series succeeded in establishing preconception health as a legitimate subject of public health concern. Whether it succeeded in moving systems is a separate question, and the honest answer is that it mostly hasn’t, yet.

There are exceptions worth noting. Several countries, including the Netherlands and Australia, have made incremental investments in preconception care pathways since 2018. Some academic medical centers have developed preconception clinics that extend counseling to men and couples with complex health histories. These are real, if bounded, examples of the framework taking institutional form.

But systematic change at the population level requires political will and sustained investment that the 2018 Series, like most medical literature, couldn’t mandate. It could only make the case. The case was made well.

What happens to it from here depends less on the research literature and more on whether health systems treat preconception health as a genuine priority rather than a background aspiration. The biological and individual-level evidence is sufficient to act on. The public health infrastructure to support that action, in most places, still isn’t.

The Series called for 5 specific policy commitments from health ministries. Most haven’t formally responded.